![]() ![]() ![]() At 4 weeks, mean ln(VEGF) changes were -0.30☐.61 pg/ml, -0.31☐.54 pg/ml, and -0.02☐.44 pg/ml for the aflibercept, bevacizumab, and ranibizumab groups, respectively. In a preplanned secondary analysis, systemic-free VEGF levels from an enzyme-linked immunosorbent assay were compared across anti-VEGF agents and correlated with systemic side effects.Ĭhanges in the natural log (ln) of plasma VEGF levels.īaseline free VEGF levels were similar across all 3 groups. Plasma samples were collected before injections at baseline and 4-week, 52-week, and 104-week visits. Participants with available plasma samples (N = 436). To assess systemic vascular endothelial growth factor (VEGF)-A levels after treatment with intravitreous aflibercept, bevacizumab, or ranibizumab.Ĭomparative-effectiveness trial with participants randomly assigned to 2 mg aflibercept, 1.25 mg bevacizumab, or 0.3 mg ranibizumab after a re-treatment algorithm. ![]()
0 Comments
Leave a Reply. |